295 related articles for article (PubMed ID: 26769007)
1. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.
Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B
Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007
[TBL] [Abstract][Full Text] [Related]
2. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.
Lo JC; Grimsrud CD; Ott SM; Chandra M; Hui RL; Ettinger B
Osteoporos Int; 2019 Dec; 30(12):2515-2520. PubMed ID: 31555883
[TBL] [Abstract][Full Text] [Related]
3. Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years.
Lo JC; Neugebauer RS; Ettinger B; Chandra M; Hui RL; Ott SM; Grimsrud CD; Izano MA
BMC Musculoskelet Disord; 2020 Dec; 21(1):801. PubMed ID: 33272248
[TBL] [Abstract][Full Text] [Related]
4. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.
Park-Wyllie LY; Mamdani MM; Juurlink DN; Hawker GA; Gunraj N; Austin PC; Whelan DB; Weiler PJ; Laupacis A
JAMA; 2011 Feb; 305(8):783-9. PubMed ID: 21343577
[TBL] [Abstract][Full Text] [Related]
7. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.
Lee YK; Ahn S; Kim KM; Suh CS; Koo KH
J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947
[TBL] [Abstract][Full Text] [Related]
8. Asian ethnicity is associated with atypical femur fractures in an Australian population study.
Nguyen HH; Lakhani A; Shore-Lorenti C; Zebaze R; Vincent AJ; Milat F; Ebeling PR
Bone; 2020 Jun; 135():115319. PubMed ID: 32179169
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.
Gedmintas L; Solomon DH; Kim SC
J Bone Miner Res; 2013 Aug; 28(8):1729-37. PubMed ID: 23408697
[TBL] [Abstract][Full Text] [Related]
10. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
11. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
12. Lateral Cortical Thickening and Bone Heterogeneity of the Subtrochanteric Femur Measured With Quantitative CT as Indicators for Early Detection of Atypical Femoral Fractures in Long-Term Bisphosphonate Users.
Lee SH; Lee YH; Suh JS
AJR Am J Roentgenol; 2017 Oct; 209(4):867-873. PubMed ID: 28796551
[TBL] [Abstract][Full Text] [Related]
13. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures.
Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC
J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684
[TBL] [Abstract][Full Text] [Related]
14. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
15. Racial/ethnic differences in hip and diaphyseal femur fractures.
Lo JC; Zheng P; Grimsrud CD; Chandra M; Ettinger B; Budayr A; Lau G; Baur MM; Hui RL; Neugebauer R
Osteoporos Int; 2014 Sep; 25(9):2313-8. PubMed ID: 24964891
[TBL] [Abstract][Full Text] [Related]
16. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
[TBL] [Abstract][Full Text] [Related]
17. Asian Ethnicity and Femoral Geometry in Atypical Femur Fractures: Independent or Interdependent Risk Factors?
Dhanekula ND; Crouch G; Byth K; Lau SL; Kim A; Graham E; Ellis A; Clifton-Bligh RJ; Girgis CM
JBMR Plus; 2022 Apr; 6(4):e10607. PubMed ID: 35434447
[TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.
Kim SY; Schneeweiss S; Katz JN; Levin R; Solomon DH
J Bone Miner Res; 2011 May; 26(5):993-1001. PubMed ID: 21542002
[TBL] [Abstract][Full Text] [Related]
19. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report.
Bissonnette L; April PM; Dumais R; Boire G; Roux S
Bone; 2013 Oct; 56(2):406-9. PubMed ID: 23871749
[TBL] [Abstract][Full Text] [Related]
20. Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy.
Qiu S; Dhaliwal R; Divine G; Warner E; Rao SD
J Bone Miner Res; 2024 May; 39(4):417-424. PubMed ID: 38477744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
